Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets.
Hepatitis C virus (HCV) binding to hepatocytes is thought to be mediated via interaction of the E2 glycoprotein with (co-)receptors including CD81 and scavenger receptor class B type I (SR-BI). Here, the expression of CD81 and SR-BI was analysed on peripheral blood mononuclear cell (PBMC) subsets, and the binding of genotype 1 soluble truncated E2 (sE2) proteins to these cells was investigated. All PBMC subsets expressed CD81, although at varying levels. In contrast, SR-BI was only detected on monocytes and dendritic cells (DCs). The genotype 1a H77c sE2 protein showed higher PBMC binding than other genotype 1a/b sE2s. H77c sE2 binding to different PBMC subsets largely paralleled their level of CD81 expression, and could be inhibited by blocking E2-CD81 interaction. However, those PBMC subsets reported to be infected by HCV in vivo (monocytes, DCs and B cells) also exhibited residual, CD81-independent binding, indicating roles for SR-BI/other receptor(s) in mediating haematopoietic cell infection.
Yamada
Eriko
E
The Edward Jenner Institute for Vaccine Research, Compton, Newbury RG20 7NN, UK.
Montoya
Maria
M
The Edward Jenner Institute for Vaccine Research, Compton, Newbury RG20 7NN, UK.
Schuettler
Christian G
CG
Institute of Medical Virology, Justus Liebig University, Giessen, Germany.
Hickling
Timothy P
TP
Division of Microbiology and Infectious Diseases, The University of Nottingham, Nottingham, UK.
Tarr
Alexander W
AW
Division of Microbiology and Infectious Diseases, The University of Nottingham, Nottingham, UK.
Vitelli
Alessandra
A
Istituto di Ricerche di Biologia Moleculare P. Angeletti, Rome, Italy.
Dubuisson
Jean
J
CNRS-UPR2511, Institut Pasteur de Lille, Lille, France.
Patel
Arvind H
AH
MRC Virology Unit, Institute of Virology, Glasgow, UK.
Ball
Jonathan K
JK
Division of Microbiology and Infectious Diseases, The University of Nottingham, Nottingham, UK.
Borrow
Persephone
P
The Edward Jenner Institute for Vaccine Research, Compton, Newbury RG20 7NN, UK.
D015703:Antigens, CD / Q000378:metabolism*; D018955:CD36 Antigens; D002460:Cell Line; D003713:Dendritic Cells / Q000378:metabolism; D005838:Genotype; D016174:Hepacivirus / Q000145:classification* / Q000235:genetics / Q000378:metabolism* / Q000472:pathogenicity; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000145:classification / Q000378:metabolism* / Q000821:virology; D009000:Monocytes / Q000378:metabolism; D011971:Receptors, Immunologic / Q000378:metabolism*; D051116:Receptors, Scavenger; D051122:Scavenger Receptors, Class B; D060225:Tetraspanin 28; D014759:Viral Envelope Proteins / Q000235:genetics / Q000378:metabolism*
D015703:Antigens, CD; D018955:CD36 Antigens; C554798:CD81 protein, human; D011971:Receptors, Immunologic; D051116:Receptors, Scavenger; C495124:SCARB1 protein, human; D051122:Scavenger Receptors, Class B; D060225:Tetraspanin 28; D014759:Viral Envelope Proteins; C091015:glycoprotein E2, Hepatitis C virus